Outlook Therapeutics, Inc.
OTLK
$0.64
$0.000.53%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -99.42% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.42% | -- | -- | -- | -- |
| Cost of Revenue | -96.13% | -- | -- | -- | -- |
| Gross Profit | -100.78% | -- | -- | -- | -- |
| SG&A Expenses | -21.99% | 19.04% | -27.91% | -0.26% | 15.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.30% | 14.23% | -43.18% | -24.72% | -11.80% |
| Operating Income | 31.36% | -13.20% | 37.59% | 24.32% | 19.50% |
| Income Before Tax | -0.83% | 90.39% | -232.69% | -360.88% | -145.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.83% | 90.39% | -232.69% | -333.56% | -145.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.83% | 90.39% | -232.69% | -333.56% | -145.38% |
| EBIT | 31.36% | -13.20% | 37.59% | 24.32% | 19.50% |
| EBITDA | 31.32% | -13.22% | 37.65% | 24.35% | 19.53% |
| EPS Basic | 72.75% | 96.38% | -153.41% | -217.42% | -128.52% |
| Normalized Basic EPS | 72.87% | 93.84% | -135.16% | -217.70% | -130.41% |
| EPS Diluted | 72.75% | 96.38% | -153.41% | -218.01% | 38.38% |
| Normalized Diluted EPS | 72.87% | 93.84% | -135.16% | -217.70% | -133.36% |
| Average Basic Shares Outstanding | 270.01% | 165.06% | 148.43% | 98.90% | 59.11% |
| Average Diluted Shares Outstanding | 270.01% | 165.06% | 148.43% | 98.90% | 45.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |